Folic acid fortification and congenital heart disease

More effective interventions are needed to target women of child bearing age

In the linked study (doi:10.1136/bmj.b1673), Ionescu-Ittu and colleagues investigate whether the 1998 government policy for mandatory fortification of flour and pasta products with folate reduced the prevalence of severe congenital heart disease at birth in Quebec, Canada. In 1997 the Teratology Society recommended folic acid supplementation to reduce the risk of neural tube defects through the fortification of staple foods. The aim was to ensure that 95% of women of child bearing age received 0.4 mg folic acid daily, with an additional 0.4 mg for those planning a pregnancy. Although the potential role of folic acid in the prevention of neural tube defects was reported as early as 1980, public health campaigns resulted in preconception supplementation in only a third of pregnant women.

The fortification policy was influenced by a Hungarian trial that reported a 90% reduction in primary neural tube defects in pregnancies supplemented by periconceptional multivitamins containing 0.8 mg folic acid. Canada initiated mandatory food fortification in 1998, and fortification of wheat flour is currently practised in 67 countries (47 in response to national mandates or regional requirements), but it has not been adopted in Europe. Folate is an important cofactor in homocysteine metabolism, and supplementation may reduce congenital malformations, including congenital heart disease, stroke, and coronary heart disease. Folate antagonists may increase congenital heart disease, particularly ventricular septal defect and conotruncal malformations. Because congenital heart disease accounts for a third of infant deaths from malformations in industrialised countries and treatment is costly, complex, and unavailable to many children, primary prevention is vital.

Ionescu-Ittu and colleagues assessed the effect of fortification with folic acid food on the prevalence of severe congenital heart disease in 1.3 million births between 1990 and 2005. They identified 2038 cases and compared changes in birth prevalence before and after fortification. Although they found no changes during the nine years before fortification, they found a 6% drop in the following seven years and concluded that mandatory fortification reduces severe congenital heart disease.

Such studies raise important questions about whether food fortification is an effective strategy, and what its effect might be. Firstly, are the current levels of fortification sufficient to significantly reduce the rates of congenital malformations? In one Canadian study, only 14% of women of child bearing age had folate concentrations that protect against neural tube defects after food fortification alone. Recommendations have therefore called for increased fortification and additional supplementation with periconceptual folic acid and vitamins.

Secondly, does fortification reduce the prevalence of severe congenital heart disease? Ionescu-Ittu and colleagues recorded cases from the physicians’ claims database and Quebec death registry when severe congenital heart disease was documented as the main cause of death. An important factor is the antenatal detection rate for congenital heart disease during this period. Any change in live birth prevalence of a malformation must take into account changes in the detection rate at screening and rates of termination of pregnancy. Both these rates are high for neural tube defects in most European countries, which results in a low live birth prevalence of 11-14%. In contrast, antenatal detection of congenital heart disease is low (about 30%), and termination of pregnancy rates have fallen for all but the most severe forms of disease. Unpublished data from St Justine Hospital’s cardiac unit, which serves half of the Quebec population, show a 5% increase (from 20% to 25%) in the antenatal diagnosis of severe congenital heart disease between the pre-fortification and post-fortification periods. Termination of pregnancy for congenital heart disease remained stable at about 40%, so antenatal diagnosis could account for a 2% reduction in birth prevalence after fortification and reduce the effect of food fortification to 2.6-4%.
Population based studies have shown a year by year variation in congenital heart disease. This, and the heterogeneity of congenital heart disease, make it difficult to ascribe causality and assess a potential gene-environment interaction—for example, the effects of no folate supplementation in families with single polymorphic mutations at nucleotide 677 of the MTHFR gene.

Thirdly, is food fortification harmful to some people? Few European countries have implemented fortification and have cited unknown health risks and freedom of choice as the reasons for this decision. Although cognitive function is improved by lowering homocysteine concentrations, as long as vitamin B12 status is normal, this must be monitored in vulnerable groups, such as elderly people. Folate may play a dual role in cancer; low doses seem protective, but time trend analyses in countries with food fortification have shown an increased risk of colorectal and breast cancer, particularly in those receiving a higher dose of 1 mg/day. Firm evidence of its effects on cardiovascular diseases is awaited. It may also have adverse effects in the unborn baby. Theoretically the epigenetic regulation of DNA through methylation may be influenced by folate and vitamin B12 availability and hence may affect the expression of oncogenes or tumour suppressor genes in offspring supplemented in utero. However, research confirming this has not yet been published.

Mandatory food fortification has reduced the prevalence of neural tube defects by about 9%, and Ionescu-Ittu and colleagues describe modest reductions in congenital heart disease. Substantial reductions in malformations have been reported only from additional periconceptual supplementation.

As the population becomes more obese, rates of type 2 diabetes increase and nutritional habits remain poor, and the prevalence of congenital heart disease may increase. So, rather than considering fortification targeted at populations, should we find more effective interventions to target women of child bearing age?

Cite this as: BMJ 2009;338:b1144

Helena M Gardiner, senior lecturer and director of perinatal cardiology, Jean-Claude Fouron, professor of fetal cardiology

Faculty of Medicine, Imperial College at Queen Charlotte’s and Chelsea and the Royal Brompton Hospitals, London W12 0NN, CHU Sainte-Justine, Montreal H3T 1C5, QC, Canada

helena.gardiner@imperial.ac.uk

Research, doi:10.1136/bmj.b1673

Competing interests: None declared.

Provenance and peer review: Commissioned; not externally peer reviewed.

References


2. Teratology Society consensus statement on use of folic acid to reduce the risk of birth defects. Teratology 1997;55:381. [CrossRef][ISI][Medline]


Folic Acid Supplementation and Spontaneous Preterm Birth: Adding Grist to the Mill?

Leonie Callaway1,2, Paul B. Colditz2,3, Nicholas M. Fisk2,3*

1 School of Medicine, The University of Queensland, Brisbane, Queensland, Australia, 2 Royal Brisbane & Women’s Hospital, Herston, Queensland, Australia, 3 University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia

Preterm birth is increasing, and complicates 12% of deliveries in the United States. It is the dominant cause of neonatal mortality. Preterm birth also accounts for one in three children with vision impairment, and almost half with cerebral palsy [1]. Babies born weighing under 2,500 g are at heightened risk in adulthood of diabetes and cardiovascular disease [1]. These short- and long-term sequelae make the prevention of preterm birth a public health priority.

Therapeutic Nihilism in Preterm Labor

Although some preterm births are indicated for maternal or fetal complications, most are spontaneous. Yet there is no licensed tocolytic agent available in the US to treat early-onset contractions, no treatment for threatened preterm labor that improves neonatal outcome, and no new class of drug under development [2]. In the face of such therapeutic nihilism, attention has turned instead to prophylaxis. There is encouraging evidence that prophylactic progesterone in women at increased risk (shortened cervix, previous history) reduces the incidence of very preterm birth [3,4]. Enthusiasm for this approach has been dampened by two setbacks. First, progesterone does not work in all pregnancies at risk of preterm labor (specifically twins). Second, 17-hydroxyprogesterone caproate recently failed to win approval from the US Food and Drug Administration due to safety concerns about fetal death rates in monkeys and humans [5,6].

Prophylactic Folic Acid: Newfound Benefit of an Old Approach?

Poor periconceptional nutrition is implicated in idiopathic preterm labor in both animal models and human studies. As with the progesterone story, there is renewed interest in decades-old suggestions that folic acid may reduce preterm birth [7–9]. Because of poor compliance with recommendations to take periconceptional folate supplements to prevent neural tube defects (NTDs), more than 50 countries have already introduced mandatory wheat flour fortification [10–12]. In California, this was associated with a modest reduction in low birthweight and preterm birth [13].

In this issue of PLoS Medicine, Radek Bukowski and colleagues report that additional voluntary folic acid supplementation was associated with a major reduction in very preterm births, those most at risk of adverse outcomes [14]. Women taking supplements for at least one year before conception had a 70% reduction in spontaneous preterm birth between 20–28 weeks, and a 50% reduction between 28–32 weeks, when compared to those with no additional supplementation. Long-term compared to no supplementation was associated with a reduction in the risk of spontaneous preterm birth before 32 weeks from one in 154 to one in 423.

Given the multiple causes of preterm labor, is this degree of hazard reduction plausible [15]? Biologically, the authors point to anti-inflammatory mechanisms. On the one hand, infection is implicated in only a minority of preterm births, but on the other, infection is found increasingly at earlier gestational ages, such as those suggested to benefit most in this study. In keeping with this mechanism, no association was seen with non-infective phenomena, such as indicated preterm birth or disorders of placenta.


Published: May 12, 2009

Copyright: © 2009 Callaway et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors received no specific funding for this article.

Competing Interests: LC declares that she has no competing interests related to this Perspective. PBC was involved with the Micronutrient Initiative in lobbying for flour fortification in Australia and New Zealand. NMF was a member of the UK Advisory Board of Ferring Pharmaceuticals until 2007, has received recent travel funds from Ferring International, the Royal College of Obstetricians and Gynaecologists, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, and the North American Fetal Treatment Network, and acts as an expert witness in medicolegal litigation in obstetrics. Between 1996–2002, he was a member of a UK lobby group (chair Prof. N. Wald) to enrich commercial flour to prevent spina bifida.

Abbreviations: NTD, neural tube defect.

* E-mail: n.fisk@uq.edu.au

Provenance: Commissioned; not externally peer reviewed
Methodologically, the study has several strengths, and is unlikely to be replicated. It is based on a huge dataset, with prospective recording of dietary supplements and potential confounders, and gestational age determined accurately on first trimester ultrasound. Those born preterm because of intervention were appropriately censored.

Nevertheless, there remains need for caution. This was a secondary analysis of a Down syndrome screening study, and so information on folic acid dose, formulation (with or without other supplements), and daily compliance is incomplete. In relation to numerators, there were only 16 births at under 32 weeks in those on long-term supplements. One unanswered question is whether women on folic acid for at least one year took a larger dose more diligently, resulting in higher folic acid levels at conception compared to women taking shorter-term supplements (women taking supplements were better educated, white, non-smoking, and different to the remaining women on nearly every measured parameter). Indeed, controlling for confounders negated the significance of any effect of less than one year’s supplementation. Long-term consumption of preconceptional folic acid supplements in other countries might suggest a subfertility/planned pregnancy effect, but Bukowski’s study occurred against the backdrop not only of mandatory flour fortification, but also recommendations in the US that all women of childbearing age, not just those planning pregnancy, consume daily 0.4 mg of folic acid over and above that in a natural diet [11].

**Obstetric Implications**

These tantalizing findings add further impetus to the study of preconceptional factors and interventions that impact on duration of pregnancy. The ultimate evidence as to whether folic acid prevents spontaneous preterm birth will require a randomized controlled trial, but conducting such a trial may prove challenging on several fronts. First, there are robust reasons to encourage all women to take folic acid. Second, one third of the world already has mandatory folic acid fortification [11]. Third are the ethical difficulties with a control group, although these might be surmounted in geographical areas where prepregnancy supplementation is not yet supported. One practical way forward would be a randomized controlled trial of ongoing folic acid supplementation in mothers with a previous very preterm birth, ideally with high-dose and low-dose arms compared to standard care to dissect out dose versus duration effects.

**Public Health Policy: Too Little, Too Late?**

There is increasing evidence that recommended supplementation levels are inadequate to optimize pregnancy outcome. Studies from North and South America show that low-level fortification of flour prevents at most only 40% of NTDs, because such fortification provides only a quarter of the recommended daily intake [16,17]. Bukowski and colleagues’ study confirms that fewer than 20% of women follow recommendations for additional folate, while in settings without mandatory fortification of flour, such as most of Europe, as few as 3% of women take the recommended 400 μg dose in the three months prior to conception [10]. Higher daily doses result in higher folate levels, and there is a continuous dose–response relationship between early pregnancy folate levels and NTD prevention [18]. Compelling arguments have been made to increase mandatory flour fortification levels 2–4 fold and pre-pregnancy folic acid tablets to 4–5 mg per day, aiming to prevent around 85% of NTDs [17]. There is little downside, now that earlier concerns about folic acid unmasking vitamin B12 deficiency appear resolved, and the evidence on whether folate supplementation increases twinning remains inconclusive [19,20].

Does Bukowski and colleagues’ study provide additional impetus for an increase in the recommended dose of folic acid [19]? No, that would be premature in the absence of intervention studies to substantiate folic acid reducing very preterm birth. This is particularly important given the experience with cardiovascular disease, where epidemiological evidence suggested protective effects of folic acid supplementation that were not borne out in subsequent randomized trials [21]. In the interim, super-supplementation can be justified entirely on the basis that it would double the number of NTDs prevented.

**Author Contributions**

ICMJE criteria for authorship read and met: LC NMF PBC. Wrote the first draft of the paper: LC NMF. Contributed to the writing of the paper: PBC.

---

**References**

Preconceptional Folate Supplementation and the Risk of Spontaneous Preterm Birth: A Cohort Study


1 University of Texas Medical Branch, Department of Obstetrics and Gynecology, Galveston, Texas, United States of America, 2 Royal College of Surgeons in Ireland, Department of Obstetrics and Gynecology, Dublin, Ireland, 3 University of Utah, Salt Lake City, Utah, United States of America, 4 The Fetal & Women’s Center of Arizona, Scottsdale, Arizona, United States of America, 5 William Beaumont Hospital, Fetial Imaging Department, Royal Oak, Michigan, United States of America, 6 Mount Sinai Medical Center, Department of Obstetrics and Gynecology, New York, New York, United States of America, 7 Montefiore Medical Center–Albert Einstein College of Medicine, Department of Obstetrics & Gynecology and Women’s Health, Bronx, New York, United States of America, 8 University of Colorado Health Sciences Center, Department of Obstetrics and Gynecology, Denver, Colorado, United States of America, 9 Tufts-New England Medical Center, Department of Obstetrics and Gynecology, Providence, Rhode Island, United States of America, 10 New York University Medical Center, School of Medicine, Department of Obstetrics and Gynecology, New York, New York, United States of America, 11 Brown University/Women & Infants’ Hospital, Department of Obstetrics and Gynecology, Providence, Rhode Island, United States of America, 12 University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Chapel Hill, North Carolina, United States of America, 13 Columbia University Medical Center, Department of Obstetrics and Gynecology, Maternal-Fetal Medicine, New York, New York, United States of America

Abstract

Background: Low plasma folate concentrations in pregnancy are associated with preterm birth. Here we show an association between preconceptional folate supplementation and the risk of spontaneous preterm birth.

Methods and Findings: In a cohort of 34,480 low-risk singleton pregnancies enrolled in a study of aneuploidy risk, preconceptional folate supplementation was prospectively recorded in the first trimester of pregnancy. Duration of pregnancy was estimated based on first trimester ultrasound examination. Natural length of pregnancy was defined as gestational age at delivery in pregnancies with no medical or obstetrical complications that may have constituted an indication for delivery. Spontaneous preterm birth was defined as duration of pregnancy between 20 and 37 wk without those complications. The association between preconceptional folate supplementation and the risk of spontaneous preterm birth was evaluated using survival analysis. Comparing to no supplementation, preconceptional folate supplementation for 1y or longer was associated with a 70% decrease in the risk of spontaneous preterm delivery between 20 and 28 wk [1 (0.27%) versus 4 (0.04%) spontaneous preterm births, respectively; HR 0.22, 95% confidence interval [CI] 0.08–0.61, p = 0.004] and a 50% decrease in the risk of spontaneous preterm delivery between 28 and 32 wk [58 (0.38%) versus 12 (0.18%) preterm birth, respectively; HR 0.45, 95% CI 0.24–0.83, p = 0.010]. Adjustment for maternal characteristics age, race, body mass index, education, marital status, smoking, parity, and history of prior preterm birth did not have a material effect on the association between folate supplementation for 1 y or longer and spontaneous preterm birth between 20 and 28 wk, and 28 to 32 wk (adjusted HR 0.31, 95% CI 0.11–0.90, p = 0.031 and 0.53, 0.28–0.99, p = 0.046, respectively). Preconceptional folate supplementation was not significantly associated with the risk of spontaneous preterm birth beyond 32 wk. The association between shorter duration (<1 y) of preconceptional folate supplementation and the risk of spontaneous preterm birth was not significant after adjustment for maternal characteristics. However, the risk of spontaneous preterm birth decreased with the duration of preconceptional folate supplementation (test for trend of survivor functions, p = 0.01) and was the lowest in women who used folate supplementation for 1 y or longer. There was also no significant association with other complications of pregnancy studied after adjustment for maternal characteristics.

Conclusions: Preconceptional folate supplementation is associated with a 50%–70% reduction in the incidence of early spontaneous preterm birth. The risk of early spontaneous preterm birth is inversely proportional to the duration of preconceptional folate supplementation. Preconceptional folate supplementation was specifically related to early spontaneous preterm birth and not associated with other complications of pregnancy.

Please see later in the article for the Editors’ Summary.
Introduction

Preterm birth is the main cause of neonatal mortality and short- and long-term morbidity. Neonatal mortality and morbidity are inversely correlated with gestational age at delivery, with the majority of those adverse outcomes associated with early preterm birth (i.e., delivery before 32 wk gestation) [1]. As a consequence, societal costs of preterm births in the US exceed US$26 billion a year [1].

Unfortunately there are no effective methods of prevention or treatment of preterm birth. The most promising intervention—progesterone supplementation—to date has been shown to be effective only in a small subset of women at risk for preterm birth [2,3]: in women with prior preterm birth or with a short cervix (≤15 mm), constituting respectively 3.3% and 1.7% of pregnancies at risk [4,5].

Several studies demonstrated an association between lower concentrations of folate and shorter duration of pregnancy. Observational studies have showed that women delivering preterm have lower concentrations of folate in plasma or red blood cells [6–9]. Results of interventional trials of folate supplementation during pregnancy are less conclusive. Supplementation of folate during pregnancy resulted in longer duration of pregnancy in some [10,11] but not in all studies [12–14].

However, a growing body of evidence of human studies and animal models suggests that duration of pregnancy may be the ultimate consequence of conditions in the very earliest stages of pregnancy or before conception [15–17]. We tested the hypothesis that preconceptional folate supplementation is associated with reduction in the risk of spontaneous preterm birth.

Methods

Study Population

In a secondary analysis of a previously described prospective cohort study [18], we studied 34,480 women who delivered singleton pregnancies between 20 wk 0 d and 42 wk 0 d. The original Down syndrome screening study was conducted at 15 US centers from October 1999 to December 2002 (Table S2). The inclusion criteria were a maternal age of 16 y or older, singleton live fetus, and a fetal crown–rump length corresponding to a gestational age of 10 wk 3 d through 13 wk 6 d at enrollment. Women were excluded from the study if they had undergone prior measurement of nuchal translucency or if anencephaly was diagnosed in the fetus.

Extensive information on patients’ demographics, medical and obstetrical history, socioeconomic status measures, and exposures during pregnancy were recorded. Copies of medical records were reviewed in all cases where parents reported a possible neonatal medical problem, in all Down syndrome screen–positive cases without karyotype results, and in a 10% random sample of all other enrolled cases by a single abstractor. Institutional review board approval was obtained in all participating centers, and all participants gave written informed consent.

Out of 42,367 patients approached, 38,033 patients were enrolled. Of those enrolled 189 (0.5%) had missing data on folate supplementation, 430 (1.1%) missing confounder data, 529 (1.4%) gestational age at delivery >42 wk, 2,103 (5.5%) missing gestational age at delivery, and 302 (0.8%) miscarried or aborted pregnancy between enrollment and 20 wk. Complete data on maternal characteristics, exposures, pregnancy complications, and outcomes were available for 34,480 (91.4%) of the remaining pregnancies.

Definition of Maternal Characteristics

Duration of consistent preconceptional folate supplementation, with or without multivitamins, was self-reported in the first trimester of pregnancy at the time of enrollment and patients were followed until delivery. Duration of preconceptional folate supplementation was reported as: <1, 1–2, 3–4, 5–6, 7–11, and >12 mo and was categorized into three groups: ≥1 y, <1 y, and no preconceptional supplementation.

Maternal age was defined as maternal age at the time of birth and categorized into <35 and ≥35 y to reflect advanced maternal age associated with increased risk of adverse pregnancy outcomes. Race and ethnicity were self-reported by mother in the first trimester of pregnancy. Maternal height and weight obtained in the first trimester of pregnancy, respectively in cm and kg, were included in calculation of body mass index. Body mass index was categorized into three groups: <20, 20–30, and >30. Maternal education level was self-reported in total completed years of education and categorized into ≤12 or >12 y. Marital status was defined as married or not married. Both education and marital status were used as measures of socioeconomic status. Smoking was defined as a self-reported smoking status of the woman in the first trimester. Prior preterm birth was defined as prior pregnancy lasting less than 37 wk 0 d.

Definition of Preterm Birth

Duration of pregnancy in all women was based on ultrasound measurement of crown–rump length in the first trimester. Preterm birth was defined as duration of pregnancy between 20 wk 0 d and 36 wk 6 d [1].

Spontaneous preterm birth was defined as preterm birth not associated with medical or obstetrical complications constituting indications for preterm delivery. Those indications included: chromosomal abnormalities, structural malformations, stillbirth, termination of pregnancy, pregnancy induced hypertension, preeclampsia, chronic hypertension, gestational or pregestational diabetes, placenta previa, and placental abruption.

Secondary Outcomes

Small for gestational age was an infant with birth weight below the 10th percentile for gestational age [19]. Preeclampsia and placental abruption were self-reported.

Statistical Analyses

Duration of preconceptional folate supplementation, categorized ≥1 y, <1 y, and no supplementation, was compared across maternal and obstetric characteristics. Univariate comparison of continuous variables was performed using the Kruskal-Wallis test and of categorical data using the Chi-square or Fisher exact tests.

All p-values are two-sided. Statistical significance is assumed at p<0.05.

The risk of spontaneous preterm birth between the categories of duration of preconceptional folate supplementation was compared using time-to-event analysis. The gestational age from 20 wk onward was used as the time scale. Gestational age at delivery between 20 wk 0 d and 36 wk 6 d was taken as time of the event in the absence of indications for delivery or as the time of censoring in either their presence or if gestational age at delivery was 37 wk 0 d or later. This approach allows assessment of the variation in relative risk of spontaneous preterm birth with gestational age.

The time to event data are presented as a cumulative percentage of the event, as recommended for rare events [20].
The univariate comparisons were made using a log-rank test. The crude and adjusted for maternal characteristics and risk factors for preterm birth hazard ratios (HRs) were obtained using Cox proportional hazard regression [21]. The risk of spontaneous preterm birth was adjusted for maternal age, race and ethnicity, body mass index in the first trimester of pregnancy, education, marital status, smoking status, parity, and history of prior preterm birth and recruitment center. The interaction terms between duration of preconceptional folate supplementation and categorized maternal characteristics and risks factors for preterm birth were assessed using Cox proportional hazard regression and multivariate logistic regression analyses. The proportional hazard assumption was tested using global and specific tests to identify categories of spontaneous preterm birth with constant HR [22].

The constancy of the log HR function was inspected visually, and identified intervals of preterm birth were tested using the proportional hazard assumption test of nonzero slope of the scaled Schoenfeld residuals of time. Goodness of fit was assessed using the test of Groennesby and Borgan [23]. Analysis of effect modification was performed using interaction terms in the proportional hazard regression and multivariable logistic regression for strata of each maternal characteristic adjusted for all other characteristics. The association between duration of preconceptional folate supplementation and the risk of preeclampsia, placental abruption, and delivery of small for gestational age infant were analyzed using multivariable logistic regression. Statistical analyses were performed using Stata 10 (Stata, http://www.stata.com/).

### Table 1. Maternal characteristics and pregnancy outcomes in relation to preconceptional folate supplementation in 34,480 singleton pregnancies.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Preconceptional Folate Supplementation</th>
<th>p-Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (% of total)</td>
<td>None (&lt;1 y) ≥1 y</td>
<td></td>
</tr>
<tr>
<td>Age, y (median IQR)</td>
<td>15,259 (44.3%) 12,444 (36.1%) 6,777 (19.6%) N/A</td>
<td></td>
</tr>
<tr>
<td>BMI (median IQR)</td>
<td>27.8 (23.5–32.5) 31.1 (27.1–34.5) 33.1 (29.4–36.3) N/A</td>
<td></td>
</tr>
<tr>
<td>Race/ethnicity, n (%)</td>
<td>24.5 (21.7–28.4) 23.3 (21.2–26.4) 23.2 (21.2–26.3) N/A</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>7,672 (50.3%) 9,931 (79.8%) 5,906 (87.1) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>5,674 (37.2%) 1,501 (12.1%) 386 (5.7) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>1,151 (7.5%) 384 (3.1%) 180 (2.7) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>599 (3.9%) 520 (4.2%) 248 (3.7) 0.6</td>
<td></td>
</tr>
<tr>
<td>Native</td>
<td>95 (0.6%) 73 (0.5%) 37 (0.5) 0.5</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>68 (0.5%) 35 (0.3%) 20 (0.3) 0.04</td>
<td></td>
</tr>
<tr>
<td>Marital status, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not married</td>
<td>5,667 (37.1%) 1,122 (9.0%) 463 (6.8) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>9,592 (62.9%) 11,322 (91.0%) 6,314 (93.2) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Education, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤12 y</td>
<td>6,769 (44.3%) 1,663 (13.4%) 608 (9.0) 0.0001</td>
<td></td>
</tr>
<tr>
<td>&gt;12 y</td>
<td>8,496 (55.7%) 10,781 (86.6%) 6,169 (91.0) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Smoking status, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nulliparous</td>
<td>1,181 (7.8%) 289 (2.3%) 149 (2.2) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Parous with no prior preterm birth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nulliparous</td>
<td>6,072 (39.8%) 6,440 (51.8%) 3,036 (44.8) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Parous with one or more preterm births</td>
<td>8,040 (52.7%) 5,290 (42.5%) 3,276 (48.3) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Duration of pregnancy, d (IQR)</td>
<td>39.4 (38.6–40.3) 39.6 (38.6–40.3) 39.4 (38.6–40.3) 0.1</td>
<td></td>
</tr>
<tr>
<td>Birth weight, g (IQR)</td>
<td>3,345 (3033–3657) 3,375 (3062–3686) 3,375 (3061–3714) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Preterm birth, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;37 wk</td>
<td>1,263 (8.3%) 894 (7.2%) 503 (7.4) 0.005</td>
<td></td>
</tr>
<tr>
<td>&lt;32 wk</td>
<td>253 (1.7%) 147 (1.2%) 73 (1.1) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Spontaneous &lt;37 wk</td>
<td>790 (5.2%) 558 (4.5%) 310 (4.6) 0.017</td>
<td></td>
</tr>
<tr>
<td>Spontaneous &lt;32 wk</td>
<td>99 (0.7%) 46 (0.4%) 16 (0.2) 0.0001</td>
<td></td>
</tr>
<tr>
<td>Nonspontaneous &lt;37 wk</td>
<td>473 (3.1%) 336 (2.7%) 193 (2.9) 0.2</td>
<td></td>
</tr>
<tr>
<td>Nonspontaneous &lt;32 wk</td>
<td>154 (1.0%) 101 (0.8%) 58 (0.9) 0.2</td>
<td></td>
</tr>
<tr>
<td>PPROM &lt;37 wk</td>
<td>204 (1.3%) 144 (1.2%) 76 (1.1) 0.1</td>
<td></td>
</tr>
<tr>
<td>PPROM &lt;32 wk</td>
<td>61 (0.4%) 34 (0.3%) 11 (0.2) 0.002</td>
<td></td>
</tr>
</tbody>
</table>

*Kruskal-Wallis test or test for trend as appropriate.
†Nonspontaneous indicates preterm birth associated with complications of pregnancy constituting indications for delivery.

DOI:10.1371/journal.pmed.1000061.t001
Results

In the study population of 34,480 women, preconceptional folic acid supplementation was used by 6,777 (19.6%) for ≥1 yr, by 12,444 (36.1%) for <1 yr, and not at all by 15,259 (44.3%) (Table 1). Preconceptional folic acid supplementation was positively associated with maternal age, education, smoking, Hispanic and black ethnicity, and preconceptional folate supplementation was associated with higher birth weight and lower rates of spontaneous preterm birth before 32 and 37 wk and preterm premature rupture of the membranes (PPROM) before 32 wk (Table 1).

A total of 2,660 women (7.7%) delivered prematurely before 37 wk, and 473 (1.4%) before 32 wk. Spontaneous preterm birth occurred in 1,658 women (4.8%) before 37 wk and in 160 (0.5%) before 32 wk (Table 1). The risk of spontaneous preterm birth decreased with the duration of preconceptional folate supplementation (test for trend of survivor functions, p = 0.01; Figure 1) and was the lowest in women who used folate supplementation for a year or longer.

The protective effect of folate supplementation decreased with advancing gestational age (Figure 1). Compared to women without preconceptional folic acid supplementation, women with a year or longer of supplementation had 70% lower risk (0.27% and 0.04%, respectively), and women with supplementation shorter than a year had 50% (0.27%) and 0.16%, respectively) lower risk of spontaneous preterm birth between 20 to 28 wk and 28 to 32 wk. The adjustment for those characteristics eliminated significant association between shorter folate supplementation and the risk of spontaneous preterm birth before 32 wk (test for trend p<0.0001) (Figure 2).

Figure 3 depicts the gradient in association between folate supplementation and risk of preterm birth. There was no significant association between duration of preconceptional folate supplementation for less than a year and spontaneous preterm birth. However, for gestational age intervals 20 to 28 wk and 28 to 32 wk, women with more than a year of supplementation had 70% lower risk (0.27% and 0.04%, respectively) of spontaneous preterm birth than women with supplementation for less than a year (0.38% and 0.18%, respectively). However, for gestational age intervals 20 to 28 wk and 28 to 32 wk, this difference was not significant (test for trend p=0.042) and proportion of spontaneous preterm birth before 32 wk (test for trend p<0.0001) (Figure 2).

Adjustment for the range of characteristics (maternal age, body mass index, race and ethnicity, educational level, marital status, smoking, parity and history of prior preterm birth) had only a minimal effect on the association between preconceptional folate supplementation and the risk of spontaneous preterm birth. Therefore, the preterm birth gestational age intervals evaluated in this study were identified by testing proportional hazard assumption, rather than selected arbitrarily and are the gestational age intervals with constant hazard ratios for spontaneous preterm birth.

The association between duration of preconceptional folate supplementation and the risk of spontaneous preterm birth was also significant when using originally reported categories of duration of folate supplementation (<1, 1–2, 3–4, 5–6, 7–11, and >12 mo). A gradient is evident with less than 1 year of supplementation in the trend of survivor functions (test for trend of survivor functions p=0.042) and proportion of spontaneous preterm birth before 32 wk (test for trend p<0.0001) (Figure 2).

Duration of preconceptional folate supplementation was also associated with significantly reduced risk of all preterm birth, spontaneous or not, in a similar manner (test for trend of survivor functions p=0.004). Thus there was a significant association between duration of preconceptional folate supplementation and the risk of preterm birth before 32 wk when pregnancies with complications constituting indication for delivery were censored or not. However, there was no significant association between duration of preconceptional folate supplementation and the risk of non-spontaneous, complicated by obstetrical or medical conditions, preterm birth.

The association between duration of preconceptional folate supplementation and the risk of spontaneous preterm birth was also significant when using originally reported categories of duration of folate supplementation (<1, 1–2, 3–4, 5–6, 7–11, and >12 mo). A gradient is evident with less than 1 year of supplementation in the trend of survivor functions (test for trend of survivor functions p=0.042) and proportion of spontaneous preterm birth before 32 wk (test for trend p<0.0001) (Figure 2).

Adjustment for the range of characteristics (maternal age, body mass index, race and ethnicity, educational level, marital status, smoking, parity and history of prior preterm birth) had only a minimal effect on the association between preconceptional folate supplementation for less than a year and spontaneous preterm birth (Table 2).

Figure 3 depicts the gradient in association between folate supplementation and risk of spontaneous preterm birth. There was
Table 2. Risk of spontaneous preterm birth and preconceptional folate supplementation.

<table>
<thead>
<tr>
<th>Preterm Birth</th>
<th>No Folate</th>
<th>Folate &lt; 1 y</th>
<th>Folate ≥ 1 y</th>
<th>Folate &lt; 1 y</th>
<th>Folate ≥ 1 y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational Age</td>
<td>No (%)</td>
<td>Incidence</td>
<td>No (%)</td>
<td>Incidence</td>
<td>No (%)</td>
</tr>
<tr>
<td>20-28 wk</td>
<td>41 (0.27)</td>
<td>0.34</td>
<td>17 (0.14)</td>
<td>0.17</td>
<td>4 (0.04)</td>
</tr>
<tr>
<td>28-32 wk</td>
<td>58 (0.38)</td>
<td>0.96</td>
<td>29 (0.23)</td>
<td>0.59</td>
<td>12 (0.18)</td>
</tr>
<tr>
<td>32-37 wk</td>
<td>691 (4.53)</td>
<td>9.21</td>
<td>512 (4.16)</td>
<td>8.33</td>
<td>295 (4.35)</td>
</tr>
</tbody>
</table>

Incidence expressed per 1,000 women per week in a gestational age period (20–28, 28–32, or 32–37 wk). Risk estimates are calculated in comparison to the group without preconceptional folate supplementation. HR adjusted for maternal age, body mass index, race and ethnicity, educational level, marital status, smoking, parity and history of prior preterm birth and recruitment center. Number needed to treat (NNT) for folate supplementation ≥ 1 y is 435 women to prevent one case of spontaneous preterm birth between 20 and 28 wk, and 500 women to prevent one spontaneous preterm birth between 28 and 32 wk.

doi:10.1371/journal.pmed.1000061.t002
was a function of the duration of preconceptional folate supplementation (adjusted HR 0.61, 95% confidence interval [CI] 0.41–0.93; \( p = 0.021 \) and 0.72, 0.54–0.96, \( p = 0.027 \), respectively). There was no significant association with the risk of spontaneous preterm birth at 32 to 37 wk (adjusted HR 0.99, 95% CI 0.92–1.07, \( p = 0.0 \)).

There were no statistically significant interactions between duration of preconceptional folate supplementation and any of the maternal characteristics or risks factors for preterm birth in predicting the risk of spontaneous preterm birth (Figure 4). Additionally, in stratified analysis the point estimates of odds ratios (ORs) did not show a pattern indicative of interaction across strata of maternal characteristics and risk factors for preterm birth (Figure 4).

Body mass index (BMI), being married, and more than 12 y of education were associated with lower risk, while Hispanic ethnicity, black or Asian race, nulliparity, and prior preterm birth were associated with higher risk of spontaneous preterm birth (Table 3). The effects of Hispanic ethnicity, black or Asian race, nulliparity, and prior preterm birth were stronger for early spontaneous preterm birth. Maternal age and smoking did not have significant effects after adjustment for remaining characteristics (Table 3).

There was no evidence of violation of the proportional hazard assumption for each variable (\( p > 0.05 \) for all) or globally for the whole model (\( p = 0.7 \)). The goodness of fit test showed no evidence of poor fit (\( p = 0.5 \)).

The proportion of the PPROM among folate supplementation groups in women with spontaneous preterm birth before 32 wk was not significantly different (20.0%, 41.3%, and 36.4%, \( p = 0.3 \); for folate supplementation for \( \geq 1 \) y, \( < 1 \) y, and no folate supplementation, respectively).

There was no significant association between duration of preconceptional folate supplementation and the risk of preeclampsia or placental abruption. The risk of delivery of a small for gestational age infant was not significant after adjustment for maternal characteristics (Table 4).

Among patients excluded from analysis who had data on preconceptional folate supplementation, folate was used by 521 (14.7%) for 1 y or longer and by 1,018 (28.6%) for less than 1 y, and was not used by 1,927 (51.4%).

**Discussion**

**Interpretation of the Key Findings**

We have shown that preconceptional folate supplementation for a year or longer is associated with a decreased risk of early spontaneous preterm birth. The association is characterized by strength, temporal relationship, biological gradient, nonsignificant effect of confounders, consistency with other studies, and biological plausibility.

Preconceptional folate supplementation for a year or longer was associated with over a 70% reduction in the risk of spontaneous preterm birth before 28 wk and 50% reduction of the risk of spontaneous preterm birth between 28 and 32 wk.

The strength of the association was significantly weaker if folate supplementation was shorter than a year. There was also a significant trend of decreased risk of spontaneous preterm birth across the original seven categories of duration of folate supplementation. This indicates existence of a biological gradient in the association between preconceptional folate supplementation and the risk of spontaneous preterm birth.

The relationship between preconceptional folate supplementation and risk of spontaneous preterm birth could potentially be confounded by risk factors for spontaneous preterm birth and indications for preterm delivery. However, adjustment for the risk factors for spontaneous preterm birth had a minimal effect on the association. The change in the coefficients observed with adjustment was 32% for spontaneous preterm birth between 20 and 28 wk and 26% for spontaneous preterm birth between 28 and 32 wk. The resulting reduction in the risk of spontaneous preterm birth, due to adjustment, of 78% versus 69% or of 55% versus 47%, respectively, is clinically of no material importance.

Pregnancies with indications for preterm delivery were censored, contributing to the denominator, the number of pregnancies at risk, but not included in the nominator, the number of spontaneous preterm births at each gestational age time point. Analysis without censoring showed a significant association between preconceptional folate supplementation and lower risk of all early preterm births. However, there was no significant association between duration of folate supplementation and the risk of nonspontaneous preterm birth.

There were no significant interactions between folate supplementation and maternal characteristics and risk factors for preterm birth, indicating that this association is observed regardless of risk factors for preterm birth. Although the confidence intervals of some of the strata were large and crossed unity due to a small size of the strata, the interaction terms of these covariates and duration of folate supplementation, which do not depend on the size of the strata, are not significant.

The findings of this study are consistent with prior observational studies showing that women delivering prematurely have lower folate concentrations in plasma or red blood cells than women delivering at term [3,24–26]. The interventional trials of folate
supplementation during pregnancy resulted in longer duration of pregnancy in some [11,27] but not in all studies [28–30]. However, those trials evaluated folate supplementation during pregnancy, most in the third trimester rather than preconceptionally, and were of insufficient size to assess early preterm birth. Trials of folate supplementation for prevention of neural tube defects did not evaluate the risk of preterm birth and had similar limitations [31–35]. However, since 1998 there has been a compulsory fortification of flour and grains with folate in the US. Thus all women enrolled in the study were exposed to mandatory folate fortification of grains. The prevalence of singleton preterm deliveries decreased after the compulsory fortification was instituted [36]. However, the decline in the incidence of preterm birth and neural tube defect was substantially less after fortification was instituted than was expected from the clinical trials [37,38]. This was attributed to insufficient amount of folate supplementation provided by folate grain fortification.

A substantial body of evidence suggests that the association between folate supplementation and spontaneous preterm birth is biologically plausible. Spontaneous preterm birth, especially at early gestation, is strongly associated with intrauterine infection [39]. Impaired function of neutrophils and lymphocytes, and increased prevalence of bacteriuria in pregnancy (a risk factor for preterm birth) are associated with low plasma folate concentrations [40–42]. Moreover, in a randomized trial, folate supplementation was shown to decrease markers of inflammation during pregnancy [43]. Recent findings have also shown an association between polymorphism or deletion in folate-metabolizing genes and the risk of preterm birth [44,45]. Biological plausibility of intrauterine infection–mediated effect of folate supplementation is also supported by lack of association with late spontaneous preterm birth. Late spontaneous preterm birth is much less strongly associated with intrauterine infection than is spontaneous preterm birth before 32 wk of pregnancy [46].

Table 3. Risk of spontaneous preterm birth in relation to maternal characteristics (n = 34,480).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Preterm Birth Gestational Age</th>
<th>n</th>
<th>Preterm Birth</th>
<th>Adjusted HR</th>
<th>95% CI</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1,322/337)</td>
<td></td>
<td></td>
<td>1.01</td>
<td>0.89–1.14</td>
<td>0.9</td>
</tr>
<tr>
<td>BMI</td>
<td></td>
<td></td>
<td></td>
<td>0.93</td>
<td>0.87–0.99</td>
<td>0.02</td>
</tr>
<tr>
<td>Race/Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td></td>
<td></td>
<td></td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>20–28 wk</td>
<td>(21/41)</td>
<td></td>
<td>1.80</td>
<td>1.20–2.71</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td>28–32 wk</td>
<td>(37/62)</td>
<td></td>
<td>1.32</td>
<td>0.98–1.77</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td>32–37 wk</td>
<td>(309/1,189)</td>
<td></td>
<td>0.95</td>
<td>0.87–1.05</td>
<td>0.3</td>
</tr>
<tr>
<td>Black</td>
<td>20–28 wk</td>
<td>(14/48)</td>
<td></td>
<td>3.00</td>
<td>1.94–4.65</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>28–32 wk</td>
<td>(9/90)</td>
<td></td>
<td>1.26</td>
<td>0.76–2.08</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>32–37 wk</td>
<td>(96/1,402)</td>
<td></td>
<td>1.10</td>
<td>0.96–1.26</td>
<td>0.2</td>
</tr>
<tr>
<td>Asian</td>
<td>20–28 wk</td>
<td>(5/57)</td>
<td></td>
<td>2.08</td>
<td>1.19–3.63</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>28–32 wk</td>
<td>(3/96)</td>
<td></td>
<td>0.80</td>
<td>0.38–1.71</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>32–37 wk</td>
<td>(60/1,438)</td>
<td></td>
<td>1.00</td>
<td>0.87–1.15</td>
<td>0.9</td>
</tr>
<tr>
<td>Married</td>
<td></td>
<td>(409/1,250)</td>
<td></td>
<td>0.93</td>
<td>0.81–1.06</td>
<td>0.3</td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td>(502/1,157)</td>
<td></td>
<td>0.87</td>
<td>0.77–0.98</td>
<td>0.034</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td>(1,561/98)</td>
<td></td>
<td>1.11</td>
<td>0.89–1.37</td>
<td>0.4</td>
</tr>
<tr>
<td>Obstetrical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nulliparous</td>
<td>20–28 wk</td>
<td>(33/29)</td>
<td></td>
<td>2.37</td>
<td>1.31–3.31</td>
<td>0.005</td>
</tr>
<tr>
<td></td>
<td>28–32 wk</td>
<td>(55/44)</td>
<td></td>
<td>2.38</td>
<td>1.55–3.74</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>32–37 wk</td>
<td>(694/804)</td>
<td></td>
<td>1.46</td>
<td>1.30–1.64</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Prior preterm birth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20–28 wk</td>
<td>(13/49)</td>
<td></td>
<td>5.46</td>
<td>2.62–11.36</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>28–32 wk</td>
<td>(15/84)</td>
<td></td>
<td>4.10</td>
<td>2.22–7.58</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>32–37 wk</td>
<td>(288/2,120)</td>
<td></td>
<td>4.38</td>
<td>3.79–5.06</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

HRs adjusted for maternal age, body mass index, race and ethnicity, educational level, marital status, smoking, parity, and history of prior preterm birth and preconceptional folate supplementation. Categorical variables: age, <35 (reference) versus ≥35 y; BMI <18.5 (reference), 18.5–25, 25–30, >30; married, not married (reference) versus married; education, ≤12 (reference) versus >12 y; smoking, nonsmoking (reference) versus smoking; nulliparous, nulliparous versus parous (reference); prior preterm birth, no prior preterm birth (reference) versus prior preterm birth. Proportional hazard assumption was met for each characteristic (proportional hazard test, p > 0.05 for all).

* = Number of spontaneous preterm births in each category in order as above or for dichotomous categories in order yes no.

doi:10.1371/journal.pmed.1000061.t003

Limitations of the Analyses

Early spontaneous preterm birth is a devastating but rare outcome. Thus the findings of this study are based on small number of cases, and additional cases may change substantially those estimates in either direction. This is reflected in their wide confidence intervals. However, the estimates remain statistically significant also using exact logistic and Poisson regressions methods, which are accurate with rare outcomes (Table S1).
Table 4. Risk of SGA infant, placental abruption, and preconceptional folate supplementation.

<table>
<thead>
<tr>
<th>Risk</th>
<th>No Folate</th>
<th>Folate &lt; 1 Y OR (95% CI)</th>
<th>Folate ≥ 1 Y OR (95% CI)</th>
<th>p-Value Adjusted</th>
<th>p-Value Adjusted</th>
<th>p-Value Adjusted</th>
<th>p-Value Adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td>SGA infant</td>
<td>15,259</td>
<td>12,444</td>
<td>6,777</td>
<td>0.001</td>
<td>0.93 (0.85–1.02)</td>
<td>0.1</td>
<td>0.82 (0.75–0.91)</td>
</tr>
<tr>
<td>Placental abruption</td>
<td>107</td>
<td>91</td>
<td>50</td>
<td>1.04 (0.78–1.39)</td>
<td>0.3</td>
<td>1.05 (0.76–1.40)</td>
<td>0.3</td>
</tr>
<tr>
<td>Preeclampsia</td>
<td>3,810</td>
<td>2,950</td>
<td>1,570</td>
<td>0.96 (0.84–1.17)</td>
<td>0.5</td>
<td>1.03 (0.85–1.25)</td>
<td>0.9</td>
</tr>
</tbody>
</table>

SGA, small for gestational age. doi:10.1371/journal.pmed.1000061.t004

A limitation of observational study design is a possibility that relevant confounders have not been accounted for. Thus, it is conceivable that folate supplementation could be a marker of healthy behavior. Such an alternative hypothesis is unlikely because the association between folate supplementation and the risk of spontaneous preterm birth is specific to spontaneous preterm birth, is not affected by other markers of healthy behavior, and depends on the length of supplementation in a similar fashion to the effect of folate supplementation on other disorders observed in randomized trials.

Preconceptional folate supplementation was associated specifically with the risk of early spontaneous preterm birth and not with the risk of other complications of pregnancy, preeclampsia, small for gestational age infant, placental abruption, or nonsmoking preterm birth. Markers of healthy behavior, maternal characteristics associated with healthy behavior, maternal age, BMI, education, marital status, and smoking minimally affected the association between folate supplementation and the risk of spontaneous preterm birth. If preconceptional folate supplementation were a mere marker of healthy behavior, adjustment for other markers of healthy behavior would either eliminate or significantly attenuate the observed association with the risk of spontaneous preterm birth. In fact, in our study, adjustment for markers of healthy behavior did not have a substantial effect.

Thus, it is unlikely that unaccounted confounders could eliminate observed associations because of the specificity of this association with only early spontaneous preterm birth and because two unaccounted confounders—markers of socioeconomic status or healthy behavior—are strongly correlated with measured confounders [1]. Moreover, some of the confounders included in the analysis may be on the mechanistic pathway of the folate effect.

Short interpregnancy interval and unintended pregnancy are unlikely to confound the findings, because the association between preconceptional folate supplementation and risk of spontaneous preterm birth was significant also in nulliparous women and largely independent of maternal age, race/ethnicity, marital status, and education, known risk factors for unintended pregnancy [47]. Conversely, subfertility is associated with multiple complications of pregnancy such as preeclampsia and delivery of small for gestational age infant, which were not associated with folate supplementation [48].

None of the above-mentioned observations is sufficient by itself to exclude the existence of unaccounted confounders, such as healthy behavior of women who use folate preconceptionally. However, collectively they strongly support a nonspurious association of preconceptional folate supplementation and the risk of spontaneous preterm birth. Definitive support for this hypothesis can be provided only by a randomized trial.

The importance of duration rather than dosage of folate supplementation has been observed previously. Meta-analyses of folate for prevention of neural tube defects or stroke did not show a significant association between dosage of folate supplementation and the strength of its effect [49,50]. Meta-analysis of randomized controlled trials of folate supplementation in stroke prevention has shown that an inverse relationship exists between the duration of folate supplementation and the risk of stroke, and that duration rather than dosage of folate supplementation is critical [51].

Finally, women who used folate supplementation preconceptionally had a lower risk of spontaneous preterm birth than women who did not use it, regardless of the unknown dosage and frequency of their use.

Use of folate in a combination with other micronutrients could potentially confound the findings. However, a systematic review and individual clinical trials have shown that supplementation with...
multiple micronutrients in pregnancy did not offer additional benefit over folate and iron supplementation alone [52–54]. In fact, supplementation with some micronutrients, such as vitamins C and E, was associated with increased risk of low birth weight [55].

Supplementation with zinc has been associated with lower risk of preterm birth [56]. However, this effect was observed primarily in the studies of low-income women. Conversely, in this study, folate supplementation was associated with a lower risk of spontaneous preterm birth regardless of the markers of socioeconomic status. Low zinc levels were also associated with placental abruption, a relationship that was not evident in this study of folate supplementation [57]. Moreover, data suggest that adding zinc may negate the beneficial effect of folate and iron on low birth weight [58,59].

Postconceptional folate supplementation also could not confound our findings. In the US 95% of women use postconceptional folate supplementation and in a population with early onset of prenatal care (as in this study) the rate is likely much higher [60]. Moreover, a systematic review of folate supplementation during pregnancy has shown no significant effect on the risk of preterm birth, duration of pregnancy, or birth weight [61].

Another limitation of this study is that preconceptional folate supplementation was self-reported at enrollment in the first trimester of pregnancy. However, self-reported folate intake from supplements has been shown to correlate with serum folate concentrations during pregnancy and was a reliable measure of folate supplementation [62]. Additionally, duration of preconceptional folate supplementation was reported prospectively, and its rate is similar to that in the general population [63]. Although a significant reduction in the risk of spontaneous preterm birth was observed across the original categories of duration of folate supplementation, we analyzed larger categories, that are consistent with other studies, and allowed analysis of confounders and interactions [64].

Implications and Generalizability

The validity and generalizability of these findings are supported by a large number and proportion of patients included in the analysis. Less than 10% of patients were excluded from the multivariable analysis. Distribution of the length of folate supplementation in the excluded pregnancies was similar to that observed in the study population. Moreover, the study population is a good representation of a general US population [65]. The incidence of early preterm birth the main outcome of the study is 1.5% in the general population and 1.4% in the study population [1]. There was no significant association between preconceptional folate supplementation and duration of pregnancy, because early spontaneous preterm birth contributes only a very small fraction to the duration of pregnancy. Univariate association with the birth weight is likely a result of confounding by risk factors for fetal growth restriction, because the association was eliminated after adjustment for maternal characteristics.

We have shown that preconceptional folate supplementation is associated with a 50%–70% reduction in the incidence of early spontaneous preterm birth. These findings, despite their limitations, provide a basis for further inquiry into preconceptional folate supplementation for prevention of spontaneous preterm birth in clinical trials.

Supporting Information

Table S1 Risk of spontaneous preterm birth and preconceptional folate supplementation: Results of maximum likelihood and exact models. Definitions: No folate, no preconceptional folate supplementation; folate <1 y, preconceptional folate supplementation for <1 year; folate ≥1 yr, preconceptional folate supplementation for ≥1 year. HR 95% CI is from Cox regression with Breslow assumption maximum likelihood model; OR 95% CI, from exact logistic regression; IRR (incidence rate ratio) 95% CI, from exact Poisson regression. Found at: doi:10.1371/journal.pmed.1000061.s001 (0.04 MB DOC)

Table S2 Participating centers. Found at: doi:10.1371/journal.pmed.1000061.s002 (0.02 MB DOC)

Acknowledgments

The authors would like to acknowledge the work of the other members of the FASTER Research Consortium: K. Welch, MS; R. Denchy, MS (Columbia University, New York); R. Ball, MD; M. Bellordi, MD; L. Cannon, BS; K. Nelson, BSN; C. Loucks, RNC; A. Yoshimura (University of Utah, and IHC prenatal centers, Salt Lake City, Provo, and Ogden, Utah); D. Luthy, MD; S. Coo, MS (Swedish Medical Center, Seattle, Washington); D. Schmidt; J. Eder, BS (William Beaumont Medical Center, Royal Oak, Michigan); G. Saade, MD; J. Lee MS (UTMB Galveston, Texas); I. Merkatz, MD; S. Carter, MS (Montefiore Medical Center, Bronx, New York); J. Hobbins, MD; L. Schultz, RN (University of Colorado Health Science Center, Denver, Colorado); M. Paidas, MD; J. Borsuk, MS (NYU Medical Center, New York); D. Bianchi, MD; B. Isquith, MS (Tufts University, Boston, Massachusetts); J. Canick, PhD; G. Messerli, PhD; C. Duquette, RDMS (Brown University, Providence, Rhode Island); R. Baughman, MS (University of North Carolina, Chapel Hill, North Carolina); K. Dukes, PhD; J. Vidaver, PhD; T. Tripp, MA; D. Emig, MPH (DM-STAT, Medford, Massachusetts).

Author Contributions

ICMJE criteria for authorship read and met: RB FDM FTP DAN CHC GDVH KE SJG LD SDC SRC HMW MED. Agree with the manuscript’s results and conclusions: RB FDM FTP DAN CHG GDVH KE SJG LD SDC IETT SRC HWM MED. Participating centers.

Table S1 Risk of spontaneous preterm birth and preconceptional folate supplementation: Results of maximum likelihood and exact models. Definitions: No folate, no preconceptional folate supplementation; folate <1 y, preconceptional folate supplementation for <1 year; folate ≥1 yr, preconceptional folate supplementation for ≥1 year. HR 95% CI is from Cox regression with Breslow assumption maximum likelihood model; OR 95% CI, from exact logistic regression; IRR (incidence rate ratio) 95% CI, from exact Poisson regression. Found at: doi:10.1371/journal.pmed.1000061.s001 (0.04 MB DOC)

Table S2 Participating centers. Found at: doi:10.1371/journal.pmed.1000061.s002 (0.02 MB DOC)

References


Editors’ Summary

Background. Most pregnancies last about 40 weeks, but sometimes the new family member arrives early. Every year, half a million babies in the United States (12.5% of all babies) are born prematurely (before 37 completed weeks of pregnancy). Sadly, premature babies are more likely to die than full-term babies and many have short- and/or long-term health problems. Premature babies often have breathing problems, they are susceptible to life-threatening infections, and they are more likely to have learning and developmental disabilities than those born on time. The severity of these health problems depends on the degree of prematurity—preterm babies born between 34 and 36 weeks of pregnancy rarely develop severe disabilities, but a quarter of babies born before 28 weeks of pregnancy develop serious lasting disabilities and half have learning and behavioral problems. Although doctors have identified some risk factors for early delivery (for example, smoking), it is impossible to predict who will have an early birth and there is no effective way to prevent preterm births.

Why Was This Study Done? Some researchers think that folic acid, a vitamin found in leafy green vegetables, fruits, and dried beans, helps to prevent neural tube birth defects. Consequently, women are encouraged to take folic acid supplements throughout (and preferably before) pregnancy and many governments now mandate that bread, pasta, and other grain products be fortified with folic acid to help women get sufficient folate. There is some evidence that women who deliver early have less folate in their blood than women who deliver at term. Furthermore, folate supplementation during pregnancy has increased the length of pregnancy in some but not all clinical trials. A possible explanation for these mixed results is that the duration of pregnancy reflects conditions in the earliest stages of pregnancy or before conception and that folate supplementation needs to start before conception to reduce the risk of preterm birth. In this study, the researchers test this idea by analyzing data collected from nearly 35,000 pregnant women enrolled in a study that was originally designed to investigate screening for Down’s syndrome.

What Did the Researchers Do and Find? During the first three months of their pregnancy, the women were asked whether they had taken folate supplements before conception. The duration of each pregnancy was estimated from ultrasound measurements taken early in the pregnancy and from the time of delivery. During the study, 1,658 women had spontaneous preterm deliveries before 37 weeks and 160 delivered before 32 weeks. After allowing for other maternal characteristics that might have affected the likelihood of preterm delivery, the risk of spontaneous preterm delivery between 20 and 28 weeks was 70% lower in women who took folate supplements for more than a year before becoming pregnant than in women who didn’t take a supplement. Long-term folate supplementation also reduced the risk of preterm delivery between 28 and 32 weeks by 50% but did not affect the risk of preterm birth beyond 32 weeks. Folate supplementation for less than a year before conception did not reduce the risk of preterm birth, and folate supplementation was not associated with any other complications of pregnancy.

What Do These Findings Mean? These findings show that folic acid supplementation for a year or more before conception is associated with a 50%–70% decrease in early (but not late) spontaneous preterm births and that the longer a woman takes folate supplements before becoming pregnant, the lower her risk of a preterm birth. Although the researchers allowed for maternal characteristics that might have affected the duration of pregnancy, it is possible that folate supplementation may not be responsible for the reduction in preterm birth risk seen in this study. For example, taking folate supplements may be a marker of healthy behavior and the women taking the supplements might have been doing something else that was reducing their risk of preterm birth. However, despite this and other limitations of this study, these findings suggest that long-term folate supplementation before conception is worth investigating further as a potential way to prevent preterm births.

Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.1000061.

- This study is further discussed in a PLoS Medicine Perspective by Nicholas Fisk
- The MedlinePlus encyclopedia contains a page on premature babies (in English and Spanish); MedlinePlus provides links to other information on premature babies (in English and Spanish)
- The US National Institute of Child Health and Human Development provides information on preterm labor and birth
- The March of Dimes, a nonprofit organization for pregnancy and baby health, provides information on preterm birth and on folic acid (in English and Spanish)
- The Nemours Foundation, another nonprofit organization for child health, also provides information on premature babies (in English and Spanish)
- The US Office of Dietary Supplements has a fact sheet on folate